In recent years, new resorces have been appearing in order to improve glycaemic control in patients with type 1 diabetes. These include new insulin analogues, glucose monitoring, smart insulin pens and hybrid close-loop systems. So, in these patients the percentage of time in range has increased, the episodes of hypoglycaemia or hyperglycaemia have decreased, and quality of life has improved. Finally, in the following years biological drugs such as teplizumab will be incorporated, which will be the first etiological treatment for type 1 diabetes.
No takes yet. Share an insight, caveat, or question.
Atance et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: